| | FTC Staff Advisory Opinion - Foundation for the Accredititation of Hematopoietic Cell Therapy |
 | | According to your letter, hematopoietic progenitor cell therapy refers generally to the infusion into a patient of blood-forming stem cells for the treatment of leukemia, certain other kinds of cancers, and some non-cancerous blood disorders. |
 | | FAHCT states that its accreditation program is intended to address concerns about the safety and quality of hematopoietic progenitor cell therapy that have arisen as the science and technology of this therapy have developed and the number of facilities performing stem cell transplants has increased. |
 | | Providing information about the quality and services of hematopoietic progenitor cell transplant services providers is potentially beneficial to consumers, and the standards do not appear, on their face, unduly to restrict competition among accredited entities in ways not reasonably related to FAHCT's legitimate purposes in establishing the standards. |
| www.ftc.gov /bc/adops/fahctlet.htm (2388 words) |